BridgeMD
New treatment option for Acute Myeloid Leukemia, Adult
Official title Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
ClinicalTrials.gov ID: NCT05703126
What this study is testing
- What it's testing
- Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of immature myeloid cells. Anthracycline antibiotics have been an integral part of the treatment of acute myeloid leukemia since the 1970s.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- patients with acute myeloid leukemia receiving anthracycline-containing polychemotherapy regimens aged 18 to 65 years, without clinical signs of...
- availability of informed consent of the patient to participate in the study.
You likely can't join if
- acute violation of cerebral circulation in history;
- a history of myocardial infarction;
- the presence of diabetes mellitus type I and II;
- the presence of chronic kidney disease C1-C5 stages;
- the presence of stable angina III-IV functional classes;
- the presence of unstable angina pectoris;
See the full eligibility criteria
- patients with acute myeloid leukemia receiving anthracycline-containing polychemotherapy regimens aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before...
- availability of informed consent of the patient to participate in the study.
- acute violation of cerebral circulation in history;
- a history of myocardial infarction;
- the presence of diabetes mellitus type I and II;
- the presence of chronic kidney disease C1-C5 stages;
- the presence of stable angina III-IV functional classes;
- the presence of unstable angina pectoris;
- the presence of atrial fibrillation and flutter;
- the presence of arterial hypertension of 2-3 degrees;
- the presence of other oncological diseases;
- inflammatory diseases in the acute stage;
- diseases of the thyroid gland;
- therapy with any monoclonal antibodies in history;
- a positive test for the presence of HIV and hepatitis B and C;
- alcoholism, drug addiction;
- the presence of neuroleukemia, extramedullary foci of leukemia;
- refusal of the patient to be examined.
- the emergence of life-threatening situations during the study;
- development in patients of diseases related to the non-inclusion criteria;
- refusal of the patient to further examination.
The study team makes the final eligibility decision.
Where it's taking place
- Samara, Samara Oblast, Russia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Samara, Samara Oblast, Russia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.